A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)

Roche Kapoor, Matthew P. Deek, Riley McIntyre, Natasha Raman, Megan Kummerlowe, Iyah Chen, Matt Gaver, Hao Wang, Sam Denmeade, Tamara Lotan, Channing Paller, Mark Markowski, Michael Carducci, Mario Eisenberger, Tomasz M. Beer, Daniel Y. Song, Theodore L. Deweese, Jason W. Hearn, Stephen Greco, Curtiland DevilleNeil B. Desai, Elisabeth I. Heath, Stanley Liauw, Daniel E. Spratt, Arthur Y. Hung, Emmanuel S. Antonarakis, Phuoc T. Tran

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)'. Together they form a unique fingerprint.

Medicine & Life Sciences